The latest announcement is out from SeaStar Medical Holding ( (ICU) ).
On January 31, 2025, SeaStar Medical Holdings entered a Securities Purchase Agreement with an institutional investor, issuing shares and warrants in both a registered direct offering and a concurrent private placement, expecting gross proceeds of approximately $6 million. The funds are intended for general corporate purposes, potentially impacting its operational capabilities and market strategy by enhancing working capital and capital expenditures.
More about SeaStar Medical Holding
SeaStar Medical is a commercial-stage therapeutic medical technology company focusing on extracorporeal therapies to reduce the impact of excessive inflammation on vital organs. The company’s innovative technologies aim to provide life-saving solutions to critically ill patients by targeting effector cells that drive systemic inflammation, causing tissue damage and imbalanced immune responses.
YTD Price Performance: 14.87%
Average Trading Volume: 378,789
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10M
For a thorough assessment of ICU stock, go to TipRanks’ Stock Analysis page.